Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the clinical efficacy of combining physiological pacing with atrioventricular node ablation in patients who have Heart Failure with preserved Ejection Fraction HFpEF and well-controlled permanent atrial fibrillation. The study aims to determine whether this combination reduces mortality and hospitalizations for heart failure compared to optimal medical therapy. This trial focuses on the potential benefit of heart rate regularization to prevent the negative effects of right ventricular apical pacing. Participants are randomly assigned to either the intervention group receiving pacemaker implantation with atrioventricular node ablation or the control group receiving optimized pharmacological therapy aimed at controlling heart rate. The pacemaker device will be programmed in VVIR mode at a lower rate of 75 beats per minute. The intervention procedures will occur within one week after randomization, and the control group will receive optimized rate control therapy according to current guidelines. Participants will visit the clinic at 3 months, 12 months, and 24 months after randomization for checkups and tests. Researchers will monitor outcomes including time to all-cause mortality or hospitalization due to heart failure or intravenous diuretics over 24 months. Secondary outcomes include cardiovascular mortality, heart failure hospitalizations, changes in clinical scores and biomarkers, and adverse events related to pacemaker implantation and ablation procedures. The total study duration extends to the end of 2029.
Actively Recruiting
The registry is designed to evaluate the outcomes, performance, and safety of BIOTRONIK devices used in conduction system pacing CSP through long-term data collected in real-world clinical settings. It includes patients who receive these devices as part of routine care to better understand their use and effects over time. The study is observational and collects data from unselected patients without intervention by the researchers. Participants receive BIOTRONIK devices for conduction system pacing, including the implantation of the Solia CSP S pacing lead for left bundle branch area pacing LBBAP. The study includes patients who are newly implanted, recently implanted but not yet discharged, or transitioning from a related study. The registry tracks device performance and safety over an average of 4 years through annual assessments. During the study, participants will undergo evaluations including the rate of device-related serious adverse events, success of acute implantation, capture type at implantation, long-term maintenance of pacing, and electrical parameters such as pacing threshold, sensing amplitude, and impedance. Participants will use the BIOTRONIK Home Monitoring system with the CardioMessenger device to support follow-up, which requires their willingness and ability to comply with study visits and monitoring over time.
Actively Recruiting
Researchers are conducting an international, multicenter, prospective, non-randomized observational study to confirm and support the clinical safety and performance of the Coroflex ISAR NEO coronary stent system. This study focuses on patients with coronary artery disease CAD or ischemic heart disease treated in real-world clinical settings to meet European Union Medical Device Regulation requirements for post-market follow-up. It involves consecutive patients treated with the sirolimus-eluting Coroflex ISAR NEO stent as intended by the manufacturer. Participants receive the Coroflex ISAR NEO coronary stent system during their routine percutaneous coronary intervention PCI procedures. This study observes patients undergoing stent placement according to standard clinical recommendations, without randomization or specific treatment assignment. The study includes patients with new lesion lengths between 2 and 4 mm and follows them after stent implantation to monitor outcomes and device performance. During the study, participants are monitored for safety and effectiveness outcomes including freedom from target lesion failure within seven days after the procedure. Additional assessments track potential complications during PCI such as accidental stent dislodgement, balloon or hypotube rupture, coronary perforation, dissection, no reflow, and thrombosis. Data collection continues according to clinical practice, with informed consent obtained and follow-up lasting up to the study completion date in February 2027.
Actively Recruiting
This research aims to observe how the Maestro Platform is used in real-life laparoscopic surgeries. The study focuses on monitoring the devices performance and any related surgical outcomes during minimally invasive procedures. The goal is to gather information on safety, procedure completion, and device reliability in routine surgical care. Participants scheduled for laparoscopic surgery will receive standard surgical care as usual, with the Maestro Platform used to assist by positioning and holding the scope and retractor as decided by the surgeon. If needed, surgeons can switch back to manual minimally invasive surgery or convert to open surgery. The study involves patients operated using the Maestro Platform and a control group. During the study, researchers will track adverse events related to the device or procedure, procedure completion without device failure, procedure duration, recovery time, post-operative pain, and surgeon satisfaction. Measurements will be taken during and up to 30 days after surgery. The study runs until December 2027, allowing comprehensive observation of outcomes and safety over this period.
Actively Recruiting
Researchers are collecting data from multiple centers in France to study cardioneuroablation as a treatment for patients with recurrent vasovagal syncope caused by strong cardioinhibitory effects. This observational registry aims to evaluate success rates, compare different techniques, and support institutions in establishing their own cardioneuroablation programs. Important questions include the procedures success, patient benefit, target sites for ablation, methods for identifying fat pads, and long-term effects. The study focuses on cardioneuroablation, a procedure using radiofrequency ablation to destroy cardiac ganglionated plexi in epicardial fat pads around the atria. Patients with recurrent vasovagal syncope who are scheduled for this procedure will be included. The registry collects data on the recurrence of syncope, efficacy of the procedure, post-ablation symptoms, correlation with ablation sites, patient quality of life, and technical learning curves at participating centers. Participants will be monitored for 12 months to track recurrence of vasovagal syncope and other outcomes. Data collection includes clinical history, procedure details, and follow-up assessments on quality of life and symptoms. The study helps to characterize patient outcomes and improve technical approaches. Participation involves no experimental treatment beyond the scheduled procedure, with data gathered during routine care and follow-up visits.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System in people with coronary artery disease who have atherosclerotic lesions longer than 36 mm and up to 44 mm in their native coronary arteries. The study focuses on lesions with a reference vessel diameter between 2.25 mm and 4.0 mm. This is a prospective, multicenter, single-arm study sponsored by Teleflex, aiming to treat subjects with these specific lesions using this device. Participants will receive the Orsiro Mission stent, which consists of a cobalt chromium stent platform coated with a bioabsorbable polymer containing the drug sirolimus. This device is designed to be implanted in the coronary arteries during percutaneous coronary intervention PCI. The study involves a single group receiving this stent to assess its performance in treating lesions of the specified length and size. During the study, participants will have follow-up visits to monitor outcomes and safety. Those enrolled in the United States will be followed for 2 years with visits at 1, 6, 12 months, and 2 years after the procedure. Participants outside the United States will be followed for 5 years with additional visits at 3 and 5 years. Researchers will measure target lesion failure at 12 months as the primary outcome and will also track device and procedure success, deaths, heart attacks, major cardiac events, revascularizations, and stent thrombosis throughout the follow-up period.